Your browser doesn't support javascript.
loading
Are Unique Regional Factors the Missing Link in India's COVID-19-Associated Mucormycosis Crisis?
Skaria, Jessy; John, Teny M; Varkey, Shibu; Kontoyiannis, Dimitrios P.
Afiliação
  • Skaria J; Independent Researcher, Houston, Texas, USA.
  • John TM; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
  • Varkey S; Maxivision Eye Hospitals, Trichy, Tamil Nadu, India.
  • Kontoyiannis DP; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Centergrid.240145.6, Houston, Texas, USA.
mBio ; 13(2): e0047322, 2022 04 26.
Article em En | MEDLINE | ID: mdl-35357212
ABSTRACT
The exact cause of the disproportionate increase in COVID-19-associated mucormycosis (CAM) cases in India remains unknown. Most researchers consider the major cause of India's CAM epidemic to be the conjunction of the COVID-19 pandemic and associated corticosteroid treatment with the enormous number of Indians with diabetes mellitus (DM). However, excess CAM cases were not seen to the same extent in the Western world, where diabetes is prevalent and corticosteroids are also used extensively for COVID-19 treatment. Herein, we hypothesize that previously overlooked environmental factors specific to India were important contributors to the country's CAM epidemic. Specifically, we propose that the spread of fungal spores, mainly through fumes generated from the burning of Mucorales-rich biomass, like cow dung and crop stubble, caused extensive environmental exposure in the context of a large population of highly vulnerable patients with DM and COVID-19. Testing this hypothesis with epidemiologic studies, phylogenetic analyses, and strategic environmental sampling may have implications for preventing future epidemics.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: COVID-19 / Tratamento Farmacológico da COVID-19 / Mucormicose Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: MBio Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: COVID-19 / Tratamento Farmacológico da COVID-19 / Mucormicose Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: MBio Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos